To review the pharmacology, antimicrobial activity, pharmacokinetics, clinical applications, and safety of ramoplanin, a lipoglycodepsipeptide antibiotic.
DATA SOURCES:
Information was obtained from MEDLINE and BIOSIS databases (1984–August 2004) and Oscient Pharmaceu ticals using the key words ramoplanin, A 16686, A 16686A, and MDL 62198.
STUDY SELECTION AND DATA EXTRACTION:
Available English-based articles and abstracts were reviewed, along with information from Oscient Pharmaceuticals.
DATA SYNTHESIS:
Ramoplanin exerts its bactericidal activity against gram-positive aerobic and anaerobic bacteria by blocking peptidoglycan synthesis via lipid II. In vitro susceptibility reports have demonstrated efficacy against antibiotic-resistant gram-positive pathogens. Cross-resistance has not been documented with vancomyin and other glycopeptides. Clinical trials are investigating ramoplanin's oral administration for treatment of Clostridium difficile–associated diarrhea. Previous clinical trials had evaluated the suppression of colonization of vancomycin-resistant Enterococcus with ramoplanin. Adverse effects are minimal, and drug—drug interactions have not been documented.
CONCLUSIONS:
The completion of clinical trials will determine whether ramoplanin has a promising role as a treatment option for diarrhea due to C. difficile.
CavalleriBPaganiHVolpeGSelvaEParentiF. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J Antibiot (Tokyo)1984; 37: 309–17.
4.
PallanzaRBertiMScottiRRandisiEArioliV. A-16686, a new antibiotic from Actinoplanes. II. Biological properties. J Antibiot (Tokyo)1984; 37: 318–24.
McCaffertyDGCudicPFankelBABarkallahSKrugerRGLiW. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers2002; 66: 261–84.
9.
BogerDL. Vancomycin, teicoplanin and ramoplanin: Synthetic and mechanistic studies. Med Res Rev2001; 21: 356–81.
10.
JiangWWannerJLeeRJBounaudPYBogerDJ. Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J Am Chem Soc2003; 125: 1877–87.
11.
HuYHelmJChenLYeXWalkerS. Ramoplanin inhibits bacterial transglycosylases as a dimer to lipid II. J Am Chem Soc2003; 125: 8736–7.
12.
JohnsonCCTaylorSPitsakisPMayPLevisonME. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother1992; 36: 2342–5.
13.
LawrenceTRotsteinCBeamTRJrGorzynskiEAAmsterdamD. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci. Antimicrob Agents Chemother1993; 37: 896–900.
14.
RomeoBKaschubeMCavenaghiLBorgonoviMJaulhacBMonteilH. Repeated doses of ramoplanin orally administered to healthy male volunteers: Tolerability, lack of absorption and effect on the stool microflora. In: Programs and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC1993; 33: 200.
15.
RewYShinDHwangIBogerDL. Total synthesis and examination of three key analogues of ramoplanin: A lipoglycodepsipeptide with potent antibiotic activity. J Am Chem Soc2004; 126: 1041–3.
16.
ChenLYuanYHelmJSHuYRewYShinD. Dissecting ramoplanin: Mechanistic analysis of synthetic ramoplanin analogues as a guide to the design of improved antibiotics. J Am Chem Soc2004; 126: 7462–3.
17.
CitronDMMerriamCVTyrrellKLWarrenYAFernandezHGoldsteinEJC. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother2003; 47: 2334–8.
18.
RolstonKVDholakiaNHoDHLeBlancBDvorakTStreeterH. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates in cancer patients. J Antimicrob Chemother1996; 38: 265–9.
19.
O'HareMDGhoshGFelminghamDGrunebergRN. In-vitro studies with ramoplanin (MDL 62,198): A novel lipoglycopeptide antimicrobial. J Antimicrob Chemother1990; 25: 217–20.
20.
NeuHCNeuNM. In vitro activity of A-16686, a new glycopeptide. Chemotherapy1986; 32: 453–7.
21.
O'HareMDFelminghamDGrunebergRN. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp. Drugs Exp Clin Res1988; 14: 617–9.
22.
ManzorOPawlakJSaravolatzL. In-vitro activity of 29 antimicrobial agents against penicillin-resistant and intermediate isolates of Streptococcus pneumoniae. J Antimicrob Chemother1999; 43: 31–6.
23.
LingLPuyangXMoirDTSinclairAWarnerMWoodfordN. In vitro activity of ramoplanin against multidrug-resistant staphylococci and enterococci (abstract 166). In: Programs and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, October 9–12, 2003.
24.
Blosser-MiddletonRSLeachTThornsberyCSahmD. In vitro activity of ramoplanin, a novel glycolipodepsipeptide, against Clostridium difficile (poster 171). In: Programs and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, October 9–12, 2003.
25.
ShonekanDMildvanDHandwergerS. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci. Antimicrob Agents Chemother1992; 36: 1570–2.
26.
CollinsLAEliopoulosGMWennerstenCBFerraroMJMoelleringRCJr. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother1993; 37: 1364–6.
27.
WiseRAndrewsJMBoswellFJAshbyJP. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother1998; 42: 721–8.
28.
BainKTWittbrodtET. Linezolid for the treatment of resistant gram-positive cocci. Ann Pharmacother2001; 35: 566–75. DOI 10.1345/aph.10276
29.
DowzidkyMNadlerHLFegerCTalbotGBompartFPeaseM. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am J Med1998; 105: 34S–42S.
30.
AuskenthalerRCourvalinPFegerCRocheG. In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci. Clin Microbiol Infect2000; 6: 608–12.
31.
DoernGVHeilmannKPHuynhHKRhombergPRCoffmanSLBrueggemannAB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother2001; 45: 1721–9.
32.
PelaezTAlcalaLAlonsoRMartin-LopezAGarcia-AriasV. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole (poster E-2188). In: Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14–17, 2003.
33.
PoutanenSSimorAE. Clostridium difficile–associated diarrhea in adults. CMAJ2004; 171: 51–8.
JohnsonSClabotsCRLinnFVOlsonMMPetersonLRGerdingDN. Nosocomial Clostridium difficile colonization and disease. Lancet1990; 336: 97–100.
36.
MillerMAHylandMOfner-AgostiniMGourdeauMIshakM. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile–associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol2002; 23: 137–40.
37.
GerdingDNJohnsonSPetersonLRMulliganMESilvaJJr. Clostridium difficile–associated diarrhea and colitis. Infect Control Hosp Epidemiol1995; 16: 459–77.
38.
FeketyR. Guidelines for the diagnosis and management of Clostridium difficile–associated diarrhea and colitis. Am J Gastroenterol1997; 92: 739–50.
39.
TailorSANBaileyEMRybakMJ. Enterococcus, an emerging pathogen. Ann Pharmacother1993; 27: 1231–42.
40.
MayhallCG. The epidemiology and control of VRE: Still struggling to come of age. Infect Control Hosp Epidemiol1999; 20: 650–2.
WongMTKauffmanCAStandifordHCLindenRFortGFuchsHJ. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis2001; 33: 1476–82.
MontecalvoMA. Ramoplanin: A novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother2003; 51 (suppl 3): 31–5.
45.
StiefelUPultzNJHelfandMSDonskeyCJ. Efficacy of oral ramoplanin for inhibition of intestinal colonization by vancomycin-resistant enterococci in mice. Antimicrob Agents Chemother2004; 48: 2144–8.
